IOL Chemicals & Pharmaceuticals Gears Up for Q3 Reveal on 11th February; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 10 Feb 2026 • 4:39 pm
Posted by:
IOL Chemicals & Pharmaceuticals Q3 results FY26 are scheduled to be announced on 11th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
IOL Chemicals & Pharmaceuticals Q3 Results 2026 Preview
- IOL Chemicals & Pharmaceuticals' revenue is expected to be in the range of ₹523.30 crore, a 0.47% YoY decrease.
- Profit After Tax, or PAT, is projected to rise 7.21% YoY.
- Net profit is ₹20.53 crore, up 7.21% YoY
- EBITDA to rise 19.30%
IOL Chemicals & Pharmaceuticals Share Performance
- Over the past six months, IOL Chemicals & Pharmaceuticals' share price has risen by 15.09% to ₹575.15.
- Moreover, over the past year, the stock has increased by 14.83%.
- Despite this weak short-term performance, IOL Chemicals & Pharmaceuticals' stock has delivered a financially sound 217.06% return over the past 5 years.
- As of 10th February 2026, the stock traded at ₹575.15 per share.
Key Factors to Watch for IOL Chemicals & Pharmaceuticals Q3 Results FY26
- Revenue Growth & Segment Trends: Performance of pharmaceutical APIs and speciality chemicals, including exports.
- Profitability & Margins: EBITDA and PAT margins are impacted by pricing, costs, and operational efficiency.
- Product Mix & Diversification: Contribution from high-value APIs versus commodity products and non-Ibuprofen portfolio expansion.
- Capacity Utilisation & Regulatory Approvals: Impact of new capacity ramp-ups and approvals supporting export growth.
- Cost Control & Balance Sheet: Management of input and energy costs, working capital, and financial flexibility.
Final Thoughts
IOL Chemicals & Pharmaceuticals will announce its Q3 FY26 results on 11th February 2026. Analysts expect 0.47% revenue growth, a 7.21% rise in PAT, and a 19.30% rise in EBITDA. IOL Chemicals & Pharmaceuticals focuses growth in API and specialty chemical sales, margin trends, product diversification beyond Ibuprofen, capacity utilisation with regulatory approvals, and cost & balance sheet management.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Alfred Herbert India Ltd Q3 Results FY26 Preview: PAT falls 3%
Salora International Q3 Results FY26 Preview: PAT falls 18.54%
Kuantum Papers Q3 Results FY26 Preview: PAT falls 29.85%
AK Capital Services Ltd Q3 Results FY26 Preview: PAT falls 16.86%
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times